



Q2 results 2010 & Update on R&D Progress

AUGUST 17, 2010

Intercell develops *vaccines* 
for the  *prevention and treatment*
of *infectious diseases* .

For more information be invited to: www.intercell.com

Forward-looking statements


These materials contain certain forward-looking statements relating to the business of Intercell AG (the “Company”), including with respect to the progress, timing and completion of the Company’s research, development and clinical trials for product candidates, the Company’s ability to manufacture, market, commercialize and achieve market acceptance for product candidates, its ability to protect its intellectual property and operate its business without infringing on the intellectual property rights of others, the Company’s estimates for future performance and its estimates regarding anticipated operating losses, future revenues, capital requirements and its needs for additional financing. In addition, even if the Company’s actual results or development are consistent with the forward-looking statements contained in this presentation, those results or developments may not be indicative of the Company’s results or developments in the future. In some cases, you can identify forward-looking statements by words such as “could,” “should,” “may,” “expects,” “anticipates,” “believes,” “intends,” “estimates,” or similar words. These forward-looking statements are based largely on the Company’s current expectations as of the date of this presentation and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the Company’s expectations could be affected by, among other things, uncertainties involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, the impact of the global credit crisis, and the Company’s ability to obtain or maintain patent or other proprietary intellectual property protection. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made during this presentation will in fact be realized. The Company is providing the information in these materials as of this date, and we disclaim any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

MANAGEMENT BOARD




Gerd Zettlmeissl, CEO

Former CEO of Chiron Behring, co-inventor of Enbrel



Thomas Lingelbach, COO

Former Vice President Industrial Operations Chiron Vaccines,
Managing Director for Novartis Vaccines Germany



Reinhard Kandra, CFO

Appointed CFO in March 2009, more than 8 years with Intercell,
formerly at Deutsche Bank

» Introduction and Highlights

Gerd Zettlmeissl, CEO

» Financial performance Q2|H1 2010

Reinhard Kandra, CFO

» Operational Update

**IXIARO[®]/JESPECT[®] &
advanced clinical programs**

Thomas Lingelbach, COO

» Outlook and next steps

Gerd Zettlmeissl, CEO

IXIARO® /JESPECT®: net product sales significantly increased to EUR 5.2m in Q2

- » Q2 sales of EUR 5.2m - best quarterly sales revenues since product launch
- » Further growth expected during 2010 by new vaccination recommendations and increasing global marketing and sales efforts
- » 2010 military sales depend on use of product stock of JE-Vax®
- » Label extension - Phase III studies for travelling children progressing according to plan
- » Clinical development in endemic areas: Phase III start in children in India planned for year end 2010*

* Conducted by
Intercell's
partner
Biological E.

Pandemic Influenza: continuation of clinical evaluation using GSK's pandemic H5N1 vaccine*

- » Results from completed Phase II not showing a statistically significant difference in seroprotection rates
- » Patch effective in delivering adjuvant and demonstrating a good safety profile
- » Timelines for initiation of next clinical trial currently under evaluation between GSK, HHS and Intercell

Clinical programs progressing well – key data expected in 2010

» Travelers' Diarrhea Vaccine Patch

- Phase III study for Travelers' Diarrhea Vaccine Patch - recruitment completed - results expected late 2010 / beginning 2011
- Complementary pilot efficacy Phase II study in travelers to India also completely recruited, data expected in Q4 2010

* As part of a collaborative agreement signed in December 2009

Clinical programs progressing well – Key data expected in 2010/2011

- » **Vaccine to prevent Pseudomonas infections:** Phase II results in hospitals expected end Q3/ beginning Q4 2010
- » **Staphylococcus aureus vaccine (V710):** First critical interim analysis (surpassing futility) expected in 2011*
- » **Pneumococcus vaccine:** Intercell and PATH evaluate design and timelines for clinical trials in children
- » **Tuberculosis vaccine:** Phase I clinical programs proceeding according to plan
- » **Therapeutic vaccine candidate against Hepatitis C:** collaboration expected in 2010 to conduct combination studies of the vaccine with a small molecule approach.

* As guided at Merck's R&D Day on May 11, 2010

Additional transactions securing growth and innovation leadership

- » Intercell acquired antibody technology for EUR 15m to complement technology platforms and open novel applications for the Antigen Identification Program (AIP®).
- » Option and Exclusive License Agreement with Boehringer Ingelheim Vetmedica to develop animal vaccines.

- » Introduction and Highlights
Gerd Zettlmeissl, CEO
- » **Financial performance Q2|H1 2010**
Reinhard Kandra, CFO
- » Operational Update
IXIARO[®]/JESPECT[®] &
advanced clinical programs
Thomas Lingelbach, COO
- » Outlook and next steps
Gerd Zettlmeissl, CEO

Solid financial position


KEY FINANCIAL FIGURES Q2|H1 2010

	3 months ended		6 months ended		Year ended
	June 30, 2010*	June 30, 2009*	June 30, 2010*	June 30, 2009*	Dec 31, 2009
<i>EUR in thousands</i>					
» Revenues	9,659	14,897	14,414	20,321	61,681
» R&D Expenses	(16,922)	(13,648)	(34,861)	(28,708)	(62,539)
» Net loss	(8,346)	(3,078)	(23,048)	(11,254)	(18,375)
» Net operating cash flow	(11,026)	(14,364)	(26,494)	(28,570)	(25,995)
» Cash and marketable securities, end of period	127,802	154,390	127,802	154,390	180,019


* unaudited

Quarterly overview Q2 2010^{*,**}


Revenues, in EUR m




R&D spending, in EUR m



Net profit/(loss), in EUR m



Cash, in EUR m



* Reporting under IFRS
 ** unaudited

Financial highlights

SITUATION ANALYSIS Q2|H1 2010*

- » **Revenues:** EUR 14.4m* revenues in H1 2010 compared to EUR 20.3* in H1 2009
- » **Product sales:** IXIARO®/JESPECT® sales revenues of EUR 5.2m* in Q2 2010
- » **COGS:** COGS of EUR 6.1m* in Q2 2010 still exceeded product sales due to high percentage of fixed costs
- » **R&D expenses:** Spending of EUR 16.9m* in Q2 2010 was mainly driven by late-stage development projects
- » **S,G&A expenses:** Increase in SG&A costs to EUR 5.2m* in Q2 2010 included transaction costs from Cytos acquisition
- » **Other operating income:** EUR 9.5m* income in Q2 2010 included gains on USD denominated financial assets and R&D tax credits
- » **Net loss** of EUR 8.3m* in Q2 2010 and EUR 23.0* in H1 2010

* Q2|H1 2010
unaudited

Financial highlights

FY 2010 FINANCIAL OUTLOOK

» **Revenues:**

- Product sales expected to continue to increase in H2 2010
- Strong collaboration & licensing income expected from milestone events and partnerships

» **COGS:** Gross margin to improve with higher capacity utilization

» **R&D expenses:** Increase in R&D expenses vs. 2009 planned for strong progression of late-stage pipeline

» **S,G&A expenses:**

- Tight cost controls in G&A expenses
- Moderate increase in sales and marketing expenses expected

» **Net loss:** FY 2010 net loss potentially higher than 2009 due to milestone shifts – expected net loss between EUR 20.0m and EUR 40.0m

» **Cash position:** EUR 127.8m* in liquid reserves at end of Q2 2010 provides comfortable basis for development of late-stage pipeline

* Q2 2010
unaudited

- » Introduction and Highlights
Gerd Zettlmeissl, CEO













- » Financial performance Q2|H1 2010
Reinhard Kandra, CFO

- » **Operational Update IXIARO[®]/
JESPECT[®] & advanced
clinical programs**
Thomas Lingelbach, COO

- » Outlook and next steps
Gerd Zettlmeissl, CEO



Commercialization structure aiming for global reach

	U.S. / EU / Japan etc.*	Asia / ROW	Australia	Military
Manu- facturing	 intercell SMART VACCINES	 Biological E. Limited	 intercell SMART VACCINES	 intercell SMART VACCINES
Marketing	 NOVARTIS	 & Biological E. Limited NOVARTIS	 CSL	 intercell SMART VACCINES
Status	<ul style="list-style-type: none"> » Licensed in U.S. & Europe in Q1 2009 » Approved in 32 countries (including US, EU27, CAN) » Launched in 16 countries 	<ul style="list-style-type: none"> » Phase III start in 2010 » Planned licensure in India (2011) and WHO pre-qualification (2012/13) 	<ul style="list-style-type: none"> » Licensed in Q1 2009 » Tenders in New Zealand and Papua New Guinea under evaluation 	<ul style="list-style-type: none"> » Exclusive supply contract with US military » Planned replacement of existing stockpile***
Trade name	 IXIARO®	 JEEV®**	 JESPECT®	 IXIARO®
Next steps	<ul style="list-style-type: none"> » Facilitate change of national recommendations for JE vaccination in travelers » Expand awareness of JE in target customers » Expand approvals into other countries and label extension in children » Develop vaccine for pediatric vaccination in endemic countries 			

* Korea, Israel, Hong Kong, Singapore, Mexico, Argentina

** Distinct product based on Intercell's manufacturing technology

*** JE-VAX®




Initial sales experience confirms need for target-oriented market development


PRODUCT SALES INTERCELL 2009/2010




Net product sales 2009



Net product sales H1 2010



Vaccine penetration among all unique travelers in the USA (2010)*



* Source: Novartis




After 10 years of product development, the market is being built up

Product Strengths

- » Unmet medical need
- » No competition (USA, EU)
- » Vaccine is safe and effective
- » Stable manufacturing process and good shelf life

Strategic Positioning



Please refer to Product / Prescribing information (PI) / Medication Guide approved in your respective countries for complete information including safety about this vaccine.

Travelers' Diarrhea vaccine – First investigational vaccine delivered with patch has entered Phase III

SUMMARY

Pivotal Phase III

- » Started in October 2009
- » Recruitment completed
- » First data expected for late 2010 / early 2011



Asian pilot efficacy Phase II

- » Started in January 2010
- » Recruitment completed
- » First data expected for Q4 2010

In an earlier Phase II field trial, the vaccine showed immunogenicity and reduced the risk of clinically significant diarrheal episodes



Estimated high likelihood of bringing Travelers' Diarrhea vaccine patch to market

DEVELOPMENT AND REGULATORY PATHWAY

2007/2008

- » First Phase II pilot efficacy data ✓
- » Production of vaccine patches at commercial scale ✓

2009


- » Start of pivotal Phase III efficacy studies ✓
- » Definition of marketing and distribution strategy ✓

2010/11/12

- » Pivotal Phase III efficacy data
- » Phase III safety and consistency data
- » Build up commercial manufacturing and supply chain
- » FDA/EMEA regulatory filings

Pandemic Influenza program with Vaccine Enhancement Patch to be continued

INJECTION PLUS PATCH



- » One dose – single application potential
- » Reduced risk of capacity shortage
- » VEP is not strain-specific – can be manufactured in advance of a pandemic



Potential of VEP to improve existing and new injectable vaccines* will be further investigated

PATH FORWARD

Key results of Phase I

- » 1 dose H5N1 vaccine** (1x45mcg) **with patch protects 73%** of subjects (vs. 49% without patch)
- » Meets FDA guideline of > 70% protection rate for Pandemic Flu vaccine
- » Excellent local and systemic safety profile

Key results of Phase II

- » No statistically significant difference observed across study groups with and without VEP
- » Endpoints
 - Dose-dependent response to H5N1 antigen observed (**not met**)
 - Safety (✓)
 - LT uptake dose dependent (✓)
- » Good safety profile (✓)
- » VEP consistently delivers vaccine adjuvant (✓)

Next steps: Proceed with clinical development investigating GSK's egg-based H5N1 vaccine in combination with Intercell's VEP

* Program funded (USD 128m) and supported by United States Department of Health & Human Services

** injected, from Solvay

*** Hemagglutinin inhibition (HI) titers



Broad Phase II/III efficacy clinical program is ongoing



S. AUREUS VACCINE STATUS

Cardiothoracic surgery (Phase II/III)*

- » **Primary Outcome:**
Prevention of serious S. aureus infections for 90 days following cardiothoracic surgery
- » First efficacy data expected for 2011**

End-stage kidney disease / dialysis (Phase II)

- » **Primary Outcome:**
Safety and immunogenicity in patients with end-stage kidney disease and hemodialysis
- » Data expected for 2010

* Adaptive design

** As guided at Merck's R&D Day on May 11, 2010, slower than anticipated enrollment and accrual of S. aureus infections

S. AUREUS DEVELOPMENT AND REGULATORY PATHWAY

2004 - 2006

- » Antigen identification and validation ✓
- » Licensing agreement with Merck & Co ✓
- » Extensive pre-clinical work in various animal models ✓

2007- 2010

- » Clinical Phase I shows robust immune response following single vaccination ✓
- » Initiation and conduct of multiple Phase II/III and Phase II studies (cardiothoracic surgery, dialysis) ✓

2011 - 2012

- » Pivotal Phase II/III data (cardiothoracic surgery)
- » Phase III safety and consistency data
- » Additional studies in extended indications (i.e. orthopedic surgery)*
- » Regulatory filings

* Optional

Extensive Phase II study of Pseudomonas vaccine in ventilated ICU patients ongoing

CLINICAL PROGRAM

Study design of ongoing Phase II

- » Randomized, placebo controlled, multicenter, double blind study
- » 400 ICU patients with mechanical ventilation
- » Primary endpoint: Immunogenicity at day 14
- » Secondary endpoint: Pseudomonas infection

Data of Phase II interim analysis*

- » Good safety and tolerability
- » Robust induction of functional antibodies
- » ~ 10% rate of Pseudomonas infections**

* 225 of 400 patients

** Invasive disease according to secondary endpoint definition

**Final data expected by Q3 2010/early Q4 2010
(depending on detailed data analysis)**



A straightforward development in hospital-acquired infections

PSEUDOMONAS DEVELOPMENT AND REGULATORY PATHWAY

2008/2009

- » Production of clinical Phase II materials ✓
- » Start of Phase II in ICU-patients ✓
- » First Phase II data ✓

2010/2011

- » Completion of Phase II
- » Potential Novartis opt-in (milestone / co-development decision)
- » Initiation of clinical Phase III

2012/2013

- » Pivotal Phase III data
- » Phase III safety and consistency data
- » Regulatory filings



A series of other attractive vaccine programs in clinical development

STATUS & NEXT STEPS

Pneumococcus vaccine*

- » Good Phase I safety and immunogenicity data
- » ICLL and PATH evaluate timeline for clinical trials in children

Hepatitis C therapeutic vaccine

- » Partnership expected in 2010
- » Conduct combination studies with a small molecule approach

Tuberculosis**

- » Phase I programs proceeding according to plan

* Supported by PATH

** Supported by AERAS, in collaboration with sanofi pasteur and SSI

- » Introduction and Highlights
Gerd Zettlmeissl, CEO

- » Financial performance Q2|H1 2010
Reinhard Kandra, CFO

- » Operational Update
IXIARO[®]/JESPECT[®] &
advanced clinical programs
Thomas Lingelbach, COO

- » **Outlook and next steps**
Gerd Zettlmeissl, CEO

Important growth steps well under way

SELECTED NEXT MILESTONES*

JE vaccine

- » First Phase III data from children for travelers' market
- » Start of Phase III in children in endemic countries
- » First approval in endemic countries

TD vaccine

- » Phase III efficacy data

S. aureus, Pseudomonas & Pneumococcus vaccines

- » Phase II/III efficacy data in S. aureus
- » Phase II data in Pseudomonas
- » Definition of industrialization & commercialization strategy for Pseudomonas
- » Phase I data in Pneumococcus –in target population


Flu and other vaccines

- » Initiation of pandemic Flu study combining VEP** and GSK's H5N1 vaccine
- » Multiple clinical data points within partnerships (e.g. Tuberculosis, Flu)
- » Strategic alliance for HCV vaccine and start of clinical combination study

AIP®, IC31® Vaccine Patch, Antibodies

- » Further out-licensing of vaccine patch (delivery and VEP**)
- » IC31® in new vaccine indications (including allergy and cancer vaccines)
- » Antibody products – definition of lead candidates

* 2010/2011
 ** Vaccine Enhancement Patch



intercell
SMART VACCINES

For more information be invited to: www.intercell.com